Enrolment completed and recommended phase II dose reached for OXC-101
Oxcia AB, today announced that it has completed enrollment and evaluation of the last patient in the MASTIFF Phase I clinical trial of OXC-101 in escalating doses for the treatment of patients with advanced solid malignant tumours. The recommended phase II dose has now been determined. Study results will be reported the coming months. “Completing enrolment in the MASTIFF study and determining the Phase 2 Recommended Dose are very significant milestone for our company and allows us to finalize planning of our phase II study” said Austin Smith, M.D, Chief Medical Officer, Oxcia. “We